Tharimmune to Present at the Microcap Conference 2025
-
Canadian Artemis II crew member to retire from space agency
-
Fritz powers past Bublik, into Wimbledon last eight again
-
Prince Harry arrives in UK amid security spat
-
Ovechkin won't say next NHL season will be his last
-
'Agony' in Cuba amid third nationwide blackout in six months
-
Djokovic, Sinner aim to book Wimbledon blockbuster
-
For Trump's World Cup, 'America First' collides with world's game
-
Record fireworks display choked Washington in toxic smoke
-
England's World Cup campaign takes flight with Mexico win
-
Macron in Syria on first post-Assad visit by West European head of state
-
Tour de France stage record still 'far away' for Pogacar
-
US streamers launch new legal fight against French content rules
-
Infantino told Trump FIFA disciplinary body is 'independent'
-
EU tells France to amend social media ban law
-
Japanese forward Hachimura signs with Clippers: reports
-
Losses from latest French museum heist estimated at 4.5 mln euros
-
After designing Taylor Swift's wedding dress, Dior's Anderson returns to catwalk
-
Big defence spending, aid cuts: German cabinet approves budget
-
Russian strikes kill 22 in Kyiv region on eve of NATO summit
-
Microsoft cuts 4,800 jobs as it revamps Xbox
-
Pogacar back in 'special' yellow after Tour de France stage three victory
-
Don't let AI shape humanity's future: UN chief
-
Paolini ends Eala run ahead of Wimbledon wildcard clash
-
Pogacar wins Tour de France 3rd stage, takes yellow
-
Austrian court sentences Syrian torturers to 8 years in jail
-
Trump confirms he asked FIFA boss for review of Balogun red card
-
Paolini ends Eala run to reach Wimbledon quarters
-
Folarin Balogun affair -- Who said what
-
Cobolli makes second successive Wimbledon quarter-final
-
Clooney to get lifetime award at Venice film festival
-
UK's Farage under the cosh over undeclared finances
-
Three things we learned from the British Grand Prix
-
Microsoft cuts 4,800 job as it revamps Xbox
-
Stock markets meander as tech recovery stutters
-
Mertens reaches Wimbledon last eight for first time
-
Britain sanctions Russian scientists behind chemical attacks
-
Rennes buy young striker Mayenda from Sunderland
-
When politics intruded on the World Cup pitch
-
Russian strikes kill 18 in Kyiv region on eve of NATO summit
-
France winger Penaud to miss remainder of Nations Championship
-
Netflix, Disney+, Amazon appeal French investment rules
-
Prince Harry set to arrive in UK amid security spat
-
Thousands flee new wave of European wildfires
-
Tottenham sign Tonali from Newcastle for reported £100m
-
Norway releases first image of crown princess after lung transplant
-
Tottenham sign Italy's Tonali from Newcastle
-
Stock markets diverge as tech recovery stutters
-
Jolted by Ebola, countries try again to finish pandemic treaty
-
Springboks recall Papier and make 10 changes for Scotland Test
-
Fashion forward: Osaka targets Wimbledon glory
NYSE - LSE
Tharimmune to Present at the Microcap Conference 2025
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time
Investors interested in meeting with management can register for the conference here.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Contacts
Tharimmune, Inc.
[email protected]
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
Contact Information
Tirth Patel
Alliance Advisors IR
[email protected]
1-212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
W.Morales--AT
